Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
J Exp Med ; 193(2): 219-31, 2001 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-11208862

RESUMO

Inflammation likely has a role in the early genesis of certain malignancies. Interleukin (IL)-15, a proinflammatory cytokine and growth factor, is required for lymphocyte homeostasis. Intriguingly, the expression of IL-15 protein is tightly controlled by multiple posttranscriptional mechanisms. Here, we engineered a transgenic mouse to overexpress IL-15 by eliminating these posttranscriptional checkpoints. IL-15 transgenic mice have early expansions in natural killer (NK) and CD8+ T lymphocytes. Later, these mice develop fatal lymphocytic leukemia with a T-NK phenotype. These data provide novel evidence that leukemia, like certain other cancers, can arise as the result of chronic stimulation by a proinflammatory cytokine.


Assuntos
Linfócitos T CD8-Positivos/imunologia , Interleucina-15/genética , Células Matadoras Naturais/imunologia , Leucemia Experimental/genética , Leucemia Experimental/imunologia , Animais , Sequência de Bases , Primers do DNA/genética , Engenharia Genética , Memória Imunológica , Mediadores da Inflamação/imunologia , Leucemia Experimental/etiologia , Linfocitose/genética , Linfocitose/imunologia , Linfocitose/patologia , Camundongos , Camundongos Transgênicos , Fenótipo , Fatores de Tempo
2.
J Clin Invest ; 106(1): 117-24, 2000 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-10880055

RESUMO

The continuous, in vivo infusion of low-dose IL-2 selectively expands the absolute number of human natural killer (NK) cells after 4-6 weeks of therapy. The mechanism responsible for this expansion is unknown and was examined in this study. NK cells cultured at low concentrations of IL-2, comparable to those found during in vivo therapy, proliferate for 6 days and then exit the cell cycle. However, NK cells in vivo did not traverse the S/G(2)/M phase of the cell cycle during low-dose IL-2 therapy. Low concentrations of IL-2 delay programmed cell death of NK cells but have the same effect on resting T cells that do not expand in vivo. When CD34(+) bone marrow hematopoietic progenitor cells are cultured for 21 days with low concentrations of IL-2, they differentiate into CD56(+)CD3(-) NK cells, not T cells. Thus, the selective expansion of human NK cells during continuous in vivo infusion of low-dose IL-2 likely results from enhanced NK-cell differentiation from bone marrow progenitors, combined with an IL-2-dependent delay in NK-cell death, rather than proliferation of mature NK cells in the periphery.


Assuntos
Interleucina-2/farmacologia , Células Matadoras Naturais/efeitos dos fármacos , Animais , Antígenos CD34/análise , Antígeno CD56/análise , Humanos , Interleucina-2/uso terapêutico , Células Matadoras Naturais/fisiologia , Ativação Linfocitária/efeitos dos fármacos , Coelhos , Proteínas Recombinantes/farmacologia
3.
Blood Cells Mol Dis ; 27(1): 223-30, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11358383

RESUMO

The role of inflammation in the early genesis of certain malignancies has recently been appreciated. Interleukin (IL)-15, a proinflammatory cytokine and growth factor, is required for lymphocyte homeostasis. Intriguingly, the expression of IL-15 protein is tightly controlled by multiple posttranscriptional mechanisms, suggesting that inappropriate expression of IL-15 may be detrimental to the host. We recently engineered a transgenic mouse in which the normal posttranscriptional control of IL-15 is eliminated, thereby overexpressing the murine IL-15 protein. IL-15 transgenic mice have early expansions in NK and CD8+ T lymphocytes and later develop fatal lymphocytic leukemia with a T-NK phenotype. This article recapitulates the phenotype of these IL-15 transgenic mice and discusses the utility of this model as a tool to further our understanding of leukemogenesis.


Assuntos
Modelos Animais de Doenças , Interleucina-15/efeitos adversos , Leucemia de Células T/etiologia , Animais , Transformação Celular Neoplásica/efeitos dos fármacos , Humanos , Interleucina-15/genética , Células Matadoras Naturais , Leucemia de Células T/mortalidade , Camundongos , Camundongos Transgênicos
4.
J Immunol ; 162(8): 4511-20, 1999 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-10201989

RESUMO

NK cells constitutively express monocyte-derived cytokine (monokine) receptors and secrete cytokines and chemokines following monokine stimulation, and are therefore a critical component of the innate immune response to infection. Here we compared the effects of three monokines (IL-18, IL-15, and IL-12) on human NK cell cytokine and chemokine production. IL-18, IL-15, or IL-12 alone did not stimulate significant cytokine or chemokine production in resting NK cells. The combination of IL-18 and IL-12 induced extremely high amounts of IFN-gamma protein (225 +/- 52 ng/ml) and a 1393 +/- 643-fold increase in IFN-gamma gene expression over those in resting NK cells. IL-15 and IL-12 induced less IFN-gamma protein (24 +/- 10 ng/ml; p < 0.007) and only a 45 +/- 19-fold increase in IFN-gamma gene expression over those in resting NK cells. The CD56bright NK cell subset produced significantly more IFN-gamma following IL-18 and IL-12 compared with CD56dim NK cells (p < 0.008). However, the combination of IL-15 and IL-12 was significantly more potent than that of IL-18 and IL-12 for NK cell production of IL-10, macrophage inflammatory protein-1alpha, macrophage inflammatory protein-1beta, and TNF-alpha at the protein and transcript levels. Granulocyte-macrophage CSF was optimally induced by IL-15 and IL-18. Resting CD56+ NK cells expressed IL-18R transcript that was up-regulated by IL-12 or IL-15. Our results show that distinct cytokine and chemokine patterns are induced in NK cells in response to different costimulatory signals from these three monokines. This suggests that NK cell cytokine production may be governed in part by the monokine milieu induced during the early proinflammatory response to infection and by the subset of NK cells present at the site of inflammation.


Assuntos
Quimiocinas/genética , Citocinas/genética , Citocinas/farmacologia , Regulação da Expressão Gênica/imunologia , Imunidade Celular , Células Matadoras Naturais/metabolismo , Ativação Linfocitária/genética , Antígeno CD56/sangue , Quimiocina CCL4 , Quimiocinas/biossíntese , Citocinas/biossíntese , Relação Dose-Resposta Imunológica , Combinação de Medicamentos , Fator Estimulador de Colônias de Granulócitos e Macrófagos/biossíntese , Humanos , Imunofenotipagem , Interferon gama/biossíntese , Interferon gama/genética , Interleucina-10/biossíntese , Interleucina-12/farmacologia , Interleucina-15/farmacologia , Interleucina-18/metabolismo , Interleucina-18/farmacologia , Subunidade alfa de Receptor de Interleucina-18 , Interfase/imunologia , Células Matadoras Naturais/imunologia , Subpopulações de Linfócitos/imunologia , Subpopulações de Linfócitos/metabolismo , Proteínas Inflamatórias de Macrófagos/biossíntese , Receptores de Interleucina/biossíntese , Receptores de Interleucina-18 , Proteínas Recombinantes/farmacologia , Transcrição Gênica/imunologia , Fator de Necrose Tumoral alfa/biossíntese
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa